Botulinum toxin for the treatment of headache: A promising path on a "dead end road"?

Acta Neurologica Belgica

Volumn 110, Issue 3, 2010, Pages 221-229

  Delstanche, Stephanie ^a   Schoenen, Jean ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Botulinum toxin; Chronic migraine; Chronic tension type headache; Migraine; OnabotulinumtoxinA

Indexed keywords

ANALGESIC AGENT; BOTULINUM TOXIN A; PLACEBO; TOPIRAMATE; VALPROIC ACID; BOTULINUM TOXIN;

ANALGESIA; CHRONIC DAILY HEADACHE; CHRONIC TENSION HEADACHE; CLINICAL TRIAL (TOPIC); DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FRONTAL TENSION HEADACHE; HEADACHE; HUMAN; MIGRAINE; MOTOR DYSFUNCTION; MUSCLE WEAKNESS; NECK PAIN; PTOSIS; REVIEW; TRANSFORMED MIGRAINE; UNSPECIFIED SIDE EFFECT; CHRONIC DISEASE; TENSION HEADACHE;

BOTULINUM TOXINS; CHRONIC DISEASE; HUMANS; MIGRAINE DISORDERS; TENSION-TYPE HEADACHE;

EID: 79952111210     PISSN: 03009009     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, et al. PREEMPT 1 Chronic Migraine Study Group - OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793-803.
2. Aurora SK, Gawel M, Brandes JL, Pokta S, VanDenburgh AM, for the BOTOX North American Episodic Migraine Study Group - Botulinum Toxin type A Prophylactic Treatment of Episodic Migraine: A randomized, Double-blind, Placebo- Controlled Exploratory Study. Headache. 2007;47(4):486-99.
3. Barrientos N, Chana P. Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study. J Headache Pain. 2003;4(3):146-51.
4. Blumenfeld A, Schim J. Botulinum toxin A compared with divalproex for the prophylactic treatment of migraine: a 9 month randomized, double-blind trial. Headache. 2008;48(2):210-20.
5. Cady R, Schreiber C. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Headache. 2008;48(6):900-13.
6. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin- induced pain. Pain, 2004;107(1-2):125-33.
7. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, et al. PREEMPT 2 Chronic Migraine Study Group - OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804-14.
8. Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, et al. BOTOX CDH Study Group. Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized, double-blind, placebo-controlled study. Headache. 2005;45(4):315-24.
9. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, et al. PREEMPT Chronic Migraine Study Group - OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double- blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache, 2010;50(6):921-36.
10. Elkind HA, O'Carroll P, Blumenfeld A, DeGryse R, Dimitrova R, for the BONTA-024-026-036 Study Group. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain. 2006;7(10):688-96.
11. Eross EJ, Gladstone JP, Lewis S, Rogers R, Dodick DW. Duration of migraine is a predictor for response to botulinum toxin A. Headache, 2005;45(4):308-14.
12. Evers S, Vollmer-Haase, Schwaag S, Rahmann A, Husstedt IW, et al. Botulinum toxin A in the prophylactic treatment of migraine- a randomized, double-blind, placebo-controlled study. Cephalalgia. 2004;24(10):838-843.
13. Evers S, Olesen J. Botulinum toxin in headache treatment: the end of the road? Cephalalgia. 2006;26(7):769-71.
14. Freitag FG, Diamond S, Diamond M, Urban G. Botulinum Toxin Type A in the Treatment of Chronic Migraine without Medication Overuse Headache. Headache. 2008;48(2):201-9.
15. Fumal A, Magis D, Schoenen J. Les céphalées par abus d'antalgiques. Rev Med Liège, 2006;61(4):217-222.
16. Jakubowski M, McAllister PJ, Bajwa ZH, Ward TN, Smith P, et al. Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A. Pain. 2006;125(3):286-95.
17. Kitamura Y, Matsuka Y, Spigelman I, Ishihara Y, Yamamoto Y, et al. Botulinum toxin type a (150 kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction. Neuroscience. 2009;10;159(4):1422-9.
18. Kokoska MS, Glaser DA, Burch CM, Hollenbeak CS. Botulinum toxin injections for the treatment of frontal tension headache. J Headache Pain. 2004;5(2):103-9.
19. Manack A, Turkel C, Silberstein S. The evolution of chronic migraine: classification and nomenclature. Headache. 2009;49(8):1206-13.
20. Mathew N, Frishberg B, Gawel M, Dimitrova R, Gibson J, et al. BOTOX CDH Study Group. Botulinum Toxin Type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, doubleblind, placebo-controlled trial. Headache. 2005;45(4):293-307.
21. Mathew NT, Kailasam J, Meadors L. Predictors of Response to Botulinum Toxin Type A (BoNTA) in Chronic Daily Headache. Headache. 2008;48(2):194-200.
22. Mathew NT, Jaffri SFA. A Double-Blind Comparison of OnabotulinumtoxinA (BOTOX®) and Topiramate (TOPAMAX®) for the Prophylactic Treatment of Chronic Migraine: A Pilot Study. Headache. 2009;49(10):1466-78.
23. Meng J, Wang J, Lawrence G, Dolly JO. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci. 2007:15;120(Pt 16):2864-74.
24. Ondo WG, Vuong KD, Derman HS. Botulinum toxin A for chronic daily headache: a randomized, placebocontrolled, parallel design study. Cephalalgia, 2004;24(1):60-5.
25. Olesen J., Bousser M-G., Diener H-C., Dodick D., First M., et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia, 2006;26(6):742-6.
26. Padberg M, de Bruijn SFMT, de Haan RJ, Tavy DLJ. Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial. Cephalalgia. 2004;24(8):675-680.
27. Relja M, Telarovic S. Botulinum toxin in tension-type headache. J Neurol 2004;251(suppl.1): I/12-I/14.
28. Relja M, Poole AC, Schoenen J, Pascual J, Lei X, et al. For the European BoNTA Headache Study Group. A multicenter, double-blind, randomized, placebocontrolled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Céphalalgia. 2007;27(6):492-503.
29. Rollnick JD, Tanneberger O, Schubert M, Schneider U, Dengler R. Treatment of tension-type headache with botulinum toxin type A: a double blind placebo controlled study. Headache. 2000;40(4):300-5.
30. Schmitt WJ, Slowey E, Fravi N, Weber S, Burgunder JM. Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double -blind, placebo-controlled trial. Headache. 2001;41(7):658-64.
31. Schoenen J. Tension-type Headache, in MacMahon S & Koltzenburg M Eds., Wall & Melzack's Textbook of Pain. 5th Edition. Elsevier, Amsterdam, 2005, Chap.56.
32. Schoenen J. Tension-type headache, in Diener H.C Ed., Drug Treatment of Migraine and Other Headaches. Monogr Clin Neurosci. Basel, Karger, 2000, vol 17, 314-21.
33. Schoenen J., Di Clemente L., Coppola G. Other prophylactic anti-migraine agents: riboflavin, feverfew, magnesium, Botulinum toxin, and calcium antagonists, in Olesen J, Silberstein SD., Tfelt-Hansen P Eds., Preventive pharmacotherapy of headache disorders. University Press, Oxford, 2004, 121-33.
34. Schulte-Mattler WJ, Krack P, BoNTTH study group. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain. 2004;109(1-2):110-4.
35. Silberstein SD, Göbel H, Jensen R, Elkind AH, DeGryse R. et al. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia. 2006;26(7):790-800.
36. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache. 2000;40(6):445-50.
37. Silberstein SD, Stark SR, Lucas SM, Christie SN, Degryse RE, et al.; BoNTA-039 Study Group. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, doubleblind, placebo-controlled trial. Mayo Clin Proc. 2005;80(9):1126-37.
38. Silberstein S, Lipton R, Dodick D, Freitag F, Mathew N, et al. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache. 2009;49(8):1153-62.
39. Smuts JA, Baker MK, Smuts HM, Rheta Stassen JM, Rossouw E, et al. Prophylactic treatment of chronic tension-type headache using botulinum toxin type A. Eur J Neurol. 1999;6(suppl 4):S99-S102.
40. Straube A, Empl M, Ceballos-Baumann A, Tölle T, Stefenelli U, et al. Dysport Tension-Type Headache Study Group. - Pericranial injection of botulinum toxin type A (Dysport) for tension-type headache - a multicentre, double-blind, randomized, placebocontrolled study. Eur J Neurol. 2008;15(3):205-13.